UniQure's experimental gene therapy, AMT-130, significantly slowed the progression of Huntington's disease, showing a 75% reduction in disease progression at 36 months in high-dose patients during an early-to-mid stage study. This positive clinical outcome for the rare inherited brain disorder led to the halting of the company's U.S.-listed shares in premarket trading, indicating strong market reaction to the potential new treatment.
UniQure (QURE) has reported highly positive data from its early-to-mid stage clinical study for AMT-130, an experimental gene therapy targeting Huntington's disease. The therapy demonstrated a significant 75% reduction in disease progression at the 36-month mark for patients in the high-dose cohort, based on a widely used clinical scale. This result represents a potential breakthrough for the rare, inherited, and fatal brain disorder, which currently has no cure. The market's perception of this news as highly material is underscored by the halt in premarket trading of the company's U.S.-listed shares. While these findings from an early-stage study are very encouraging and de-risk the asset to a degree, the path to commercialization still requires further clinical validation in larger, later-stage trials and subsequent regulatory approval.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.80
Ticker Sentiment
